Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027
The multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8% during the forecast period. The burden of chronic diseases has necessitated the use of multiplex assays for containment and management. As many biomarkers are being discovered and validated, there is a higher probability of the development of new diagnostic tests. At present, there are only a few multiplex assays targeting specific disease classes. With the development of new biomarkers, new multiplex assays can be developed. Owing to this, biomarker validation can create opportunities for the development of the multiplex assays market. However, high instrument cost is a major factor limiting the wider adoption of multiplex assays.
“The consumables segment accounted for the highest growth rate in the multiplex assays market, by product & service, during the forecast period”
Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. This segment is also expected to grow at the highest CAGR. The instruments segment accounted for the second largest share of the multiplex assays market. The increasing incidence of infectious diseases & cancer, growing demand for automated and advanced instruments with high-throughput capacities and increasing need for faster and more accurate test results with minimal human intervention are driving the instruments market segment.
“The research & development segment accounted for the highest growth rate in the multiplex assays market, by application, during the forecast period”
Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment accounted the largest share of the multiplex assays market in 2022. The drug discovery & development segment accounted for the largest share of the multiplex assays market for research & development in 2022. The demand for multiplex assays in drug discovery & development has increased due to their benefits. These assays tend to be effective in evaluating drug response biomarkers, immunotherapy success, and toxicity during the clinical stages of drug development.
“Asia Pacific: The fastest-growing region multiplex assays market”
The global multiplex assays market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as growing government efforts to increase awareness about the early detection of diseases and the increasing number of regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and growing strength in the research base for diagnostic procedures across India, China, and Japan.
The break-up of the profile of primary participants in the multiplex assays market:
Research Coverage:
This research report categorizes the multiplex assays market by product & service (consumables, instruments, and software & services), type (protein multiplex assays [planar protein assays, bead-based protein assays, and other protein assays], nucleic acid multiplex assays [planar nucleic acid assays, bead-based nucleic acid assays, and other nucleic acid assays], and cell-based Multiplex Assays), technology (flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies), application (research & development [drug discovery & development and biomarker discovery & validation] and clinical diagnostics [infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders, and other diseases]), end user (pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories, and other end users), and region (North America, Europe, Asia Pacific, and the Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the multiplex assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the multiplex assays market. Competitive analysis of upcoming startups in the multiplex assays market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall multiplex assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The consumables segment accounted for the highest growth rate in the multiplex assays market, by product & service, during the forecast period”
Based on product & service, the multiplex assays market is segmented into three broad categories, namely, consumables, instruments, and software & services. In 2022, the consumables segment accounted for the largest share of the market. This segment is also expected to grow at the highest CAGR. The instruments segment accounted for the second largest share of the multiplex assays market. The increasing incidence of infectious diseases & cancer, growing demand for automated and advanced instruments with high-throughput capacities and increasing need for faster and more accurate test results with minimal human intervention are driving the instruments market segment.
“The research & development segment accounted for the highest growth rate in the multiplex assays market, by application, during the forecast period”
Based on applications, the multiplex assays market is segmented into research & development (drug discovery & development and biomarker discovery & validation) and clinical diagnostics (infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases). The research & development application segment accounted the largest share of the multiplex assays market in 2022. The drug discovery & development segment accounted for the largest share of the multiplex assays market for research & development in 2022. The demand for multiplex assays in drug discovery & development has increased due to their benefits. These assays tend to be effective in evaluating drug response biomarkers, immunotherapy success, and toxicity during the clinical stages of drug development.
“Asia Pacific: The fastest-growing region multiplex assays market”
The global multiplex assays market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as growing government efforts to increase awareness about the early detection of diseases and the increasing number of regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and growing strength in the research base for diagnostic procedures across India, China, and Japan.
The break-up of the profile of primary participants in the multiplex assays market:
- By Company Type: Tier 1 - 42%, Tier 2 - 37%, and Tier 3 - 21%
- By Designation: C-level - 34%, D-level - 42%, and Others - 24%
- By Region: North America - 32%, Europe - 30%, Asia Pacific - 24%, and the Rest of the World – 14%
Research Coverage:
This research report categorizes the multiplex assays market by product & service (consumables, instruments, and software & services), type (protein multiplex assays [planar protein assays, bead-based protein assays, and other protein assays], nucleic acid multiplex assays [planar nucleic acid assays, bead-based nucleic acid assays, and other nucleic acid assays], and cell-based Multiplex Assays), technology (flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies), application (research & development [drug discovery & development and biomarker discovery & validation] and clinical diagnostics [infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders, and other diseases]), end user (pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories, and other end users), and region (North America, Europe, Asia Pacific, and the Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the multiplex assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the multiplex assays market. Competitive analysis of upcoming startups in the multiplex assays market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall multiplex assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (increasing use of multiplex assays in companion diagnostics, increasing advantages over singleplex and traditional assays, and increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis), restraints (rising costs of equipment and growing number of stringent regulations and standards), opportunities (increasing validation of biomarkers in molecular and protein diagnostics and rising need for high-throughput and automated systems), and challenges (increasing dearth of skilled professionals) influencing the growth of the multiplex assays market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assays market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the multiplex assays market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the multiplex assays market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany) among others in the multiplex assays market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNITS CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MULTIPLEX ASSAYS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MULTIPLEX ASSAYS MARKET
2.10 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MULTIPLEX ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MULTIPLEX ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MULTIPLEX ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW
FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
4.2 MULTIPLEX ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
4.3 MULTIPLEX ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.4 MULTIPLEX ASSAYS MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE
4.5 MULTIPLEX ASSAYS MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE
4.6 MULTIPLEX ASSAYS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.7 MULTIPLEX ASSAYS MARKET: REGIONAL GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing use of multiplex assays in companion diagnostics
5.2.1.2 Increasing advantages over singleplex and traditional assays
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045
TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2
5.2.2 RESTRAINTS
5.2.2.1 Rising costs of equipment
5.2.2.2 Growing number of stringent regulations and standards
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics
5.2.3.2 Rising need for high-throughput and automated systems
5.2.4 CHALLENGES
5.2.4.1 Increasing dearth of skilled professionals
TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020
5.3 CUSTOMIZATION DATA
TABLE 5 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 PRIMARY NOTES
6.2.1 KEY INDUSTRY INSIGHTS
6.3 CONSUMABLES
6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 MULTIPLEX ASSAYS MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 13 MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.2 PROTEIN MULTIPLEX ASSAYS
TABLE 14 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 15 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 PLANAR PROTEIN ASSAYS
7.2.1.1 Pivotal role in drug discovery to support uptake
TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 BEAD-BASED PROTEIN ASSAYS
7.2.2.1 Best suited to study protein-protein interactions
TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 OTHER PROTEIN ASSAYS
TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 NUCLEIC ACID MULTIPLEX ASSAYS
TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2
TABLE 24 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 25 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.1 PLANAR NUCLEIC ACID ASSAYS
7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS
7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market
TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.3 OTHER NUCLEIC ACID ASSAYS
TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 CELL-BASED MULTIPLEX ASSAYS
7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
TABLE 33 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 35 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 FLOW CYTOMETRY
8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST
TABLE 36 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 FLUORESCENCE DETECTION
8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH
TABLE 38 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 LUMINESCENCE
8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
TABLE 40 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 MULTIPLEX REAL-TIME PCR
8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
TABLE 42 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 44 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 46 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 RESEARCH & DEVELOPMENT
TABLE 47 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.1 DRUG DISCOVERY & DEVELOPMENT
9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
TABLE 50 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.2 BIOMARKER DISCOVERY & VALIDATION
9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in large samples
TABLE 52 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
TABLE 54 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.1 INFECTIOUS DISEASES
9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
TABLE 57 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.2 CANCER
9.3.2.1 Rising burden of cancer to drive market
TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
TABLE 61 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.3 CARDIOVASCULAR DISEASES
9.3.3.1 High burden of cardiovascular diseases to support market growth
TABLE 63 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.4 AUTOIMMUNE DISEASES
9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES
TABLE 66 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.5 NERVOUS SYSTEM DISORDERS
9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
TABLE 68 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions
TABLE 70 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.7 OTHER DISEASES
TABLE 72 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
10 MULTIPLEX ASSAYS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 74 MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE
TABLE 75 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 HOSPITALS & RESEARCH INSTITUTES
10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
TABLE 77 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 REFERENCE LABORATORIES
10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH
TABLE 79 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.5 OTHER END USERS
TABLE 81 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 82 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
11 MULTIPLEX ASSAYS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 83 MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 86 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
FIGURE 23 NORTH AMERICA: MULTIPLEX ASSAYS MARKET SNAPSHOT
11.2.1 RECESSION IMPACT ON NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 91 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 93 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 94 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth
TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 96 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 98 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 99 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 102 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 104 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 105 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 RECESSION IMPACT ON EUROPE
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT
TABLE 106 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 RECESSION IMPACT ON ASIA PACIFIC
11.5 REST OF THE WORLD
TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 112 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 114 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 115 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 RECESSION IMPACT ON REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017–2021)
12.4 MARKET SHARE ANALYSIS
12.4.1 MULTIPLEX ASSAYS MARKET
FIGURE 26 MULTIPLEX ASSAYS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 117 MULTIPLEX ASSAYS MARKET: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 27 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 28 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023)
12.7.2 DEALS
TABLE 119 KEY DEALS (2020-2023)
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ILLUMINA, INC.
TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022)
13.1.2 BIO-RAD LABORATORIES, INC.
TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022)
13.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022)
13.1.5 DIASORIN S.P.A.
TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021)
13.1.6 QIAGEN N.V.
TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021)
13.1.7 ABCAM PLC
TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021)
13.1.8 MERCK KGAA
TABLE 127 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022)
13.1.9 AGILENT TECHNOLOGIES, INC.
TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022)
13.1.10 QUANTERIX
TABLE 129 QUANTERIX: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022)
13.1.11 BIO-TECHNE
TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021)
13.1.12 MESO SCALE DIAGNOSTICS, LLC
TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
13.1.13 RANDOX LABORATORIES LTD.
TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 OLINK
TABLE 133 OLINK: COMPANY OVERVIEW
13.2.2 SEEGENE INC.
TABLE 134 SEEGENE INC.: COMPANY OVERVIEW
13.2.3 SIEMENS HEALTHINEERS AG
TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
13.2.4 PERKINELMER INC.
TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW
13.2.5 SHIMADZU CORPORATION
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
13.2.6 PROMEGA CORPORATION
TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW
13.2.7 ENZO BIOCHEM INC.
TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW
13.2.8 CAYMAN CHEMICAL
TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW
13.2.9 BOSTER BIOLOGICAL TECHNOLOGY
TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
13.2.10 ANTIGENIX AMERICA, INC.
TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW
13.2.11 QUANSYS BIOSCIENCES INC.
TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW
13.2.12 RAYBIOTECH LIFE, INC.
TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 UNITS CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MULTIPLEX ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MULTIPLEX ASSAYS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MULTIPLEX ASSAYS MARKET
2.10 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 8 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MULTIPLEX ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MULTIPLEX ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MULTIPLEX ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MULTIPLEX ASSAYS MARKET OVERVIEW
FIGURE 14 INCREASING ADOPTION OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
4.2 MULTIPLEX ASSAYS MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 15 CONSUMABLES PRODUCT & SERVICE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
4.3 MULTIPLEX ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 16 PROTEIN MULTIPLEX ASSAYS TYPE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.4 MULTIPLEX ASSAYS MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 17 FLOW CYTOMETRY TECHNOLOGY TO ACCOUNT FOR LARGEST MARKET SHARE
4.5 MULTIPLEX ASSAYS MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 18 RESEARCH & DEVELOPMENT APPLICATION TO ACCOUNT FOR LARGER MARKET SHARE
4.6 MULTIPLEX ASSAYS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES END USER SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
4.7 MULTIPLEX ASSAYS MARKET: REGIONAL GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MULTIPLEX ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing use of multiplex assays in companion diagnostics
5.2.1.2 Increasing advantages over singleplex and traditional assays
5.2.1.3 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, IN 2021, 2030, AND 2045
TABLE 1 TOTAL HEALTH EXPENDITURE DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
TABLE 3 APPROVED AND LAUNCHED MULTIPLEX ASSAYS FOR DIAGNOSIS OF SARS-COV-2
5.2.2 RESTRAINTS
5.2.2.1 Rising costs of equipment
5.2.2.2 Growing number of stringent regulations and standards
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing validation of biomarkers in molecular and protein diagnostics
5.2.3.2 Rising need for high-throughput and automated systems
5.2.4 CHALLENGES
5.2.4.1 Increasing dearth of skilled professionals
TABLE 4 NUMBER OF LAB TECHNOLOGISTS AND TECHNICIANS IN US, 2020
5.3 CUSTOMIZATION DATA
TABLE 5 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 6 MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 PRIMARY NOTES
6.2.1 KEY INDUSTRY INSIGHTS
6.3 CONSUMABLES
6.3.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET
TABLE 7 MULTIPLEX ASSAY CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 8 NORTH AMERICA: MULTIPLEX ASSAY CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH
TABLE 9 MULTIPLEX ASSAY INSTRUMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 10 NORTH AMERICA: MULTIPLEX ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE
TABLE 11 MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 12 NORTH AMERICA: MULTIPLEX ASSAY SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 MULTIPLEX ASSAYS MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 13 MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.2 PROTEIN MULTIPLEX ASSAYS
TABLE 14 PROTEIN MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 15 PROTEIN MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 NORTH AMERICA: PROTEIN MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 PLANAR PROTEIN ASSAYS
7.2.1.1 Pivotal role in drug discovery to support uptake
TABLE 17 PLANAR PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: PLANAR PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 BEAD-BASED PROTEIN ASSAYS
7.2.2.1 Best suited to study protein-protein interactions
TABLE 19 BEAD-BASED PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: BEAD-BASED PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 OTHER PROTEIN ASSAYS
TABLE 21 OTHER PROTEIN ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: OTHER PROTEIN ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 NUCLEIC ACID MULTIPLEX ASSAYS
TABLE 23 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA AND SARS-COV-2
TABLE 24 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 25 NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.1 PLANAR NUCLEIC ACID ASSAYS
7.3.1.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis
TABLE 27 PLANAR NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 NORTH AMERICA: PLANAR NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.2 BEAD-BASED NUCLEIC ACID ASSAYS
7.3.2.1 Increasing infectious diseases and genetic screening tests to drive market
TABLE 29 BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: BEAD-BASED NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.3 OTHER NUCLEIC ACID ASSAYS
TABLE 31 OTHER NUCLEIC ACID ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: OTHER NUCLEIC ACID ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 CELL-BASED MULTIPLEX ASSAYS
7.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET
TABLE 33 CELL-BASED MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL-BASED MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 35 MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 FLOW CYTOMETRY
8.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO MAKE THIS MARKET SEGMENT LARGEST
TABLE 36 MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 FLUORESCENCE DETECTION
8.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL GROWTH
TABLE 38 MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 LUMINESCENCE
8.4.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET
TABLE 40 MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR LUMINESCENCE, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 MULTIPLEX REAL-TIME PCR
8.5.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS
TABLE 42 MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR MULTIPLEX REAL-TIME PCR, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 44 MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
9 MULTIPLEX ASSAYS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 46 MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 RESEARCH & DEVELOPMENT
TABLE 47 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.1 DRUG DISCOVERY & DEVELOPMENT
9.2.1.1 Multiplex assays massively employed in preclinical and clinical phases
TABLE 50 MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
9.2.2 BIOMARKER DISCOVERY & VALIDATION
9.2.2.1 Multiplex assays aid in quantitative measurement of protein biomarkers in large samples
TABLE 52 MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CLINICAL DIAGNOSTICS
TABLE 54 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.1 INFECTIOUS DISEASES
9.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays
TABLE 57 MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.2 CANCER
9.3.2.1 Rising burden of cancer to drive market
TABLE 59 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 60 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
TABLE 61 MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.3 CARDIOVASCULAR DISEASES
9.3.3.1 High burden of cardiovascular diseases to support market growth
TABLE 63 MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.4 AUTOIMMUNE DISEASES
9.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis
TABLE 65 PREVALENCE OF SOME AUTOIMMUNE DISEASES
TABLE 66 MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.5 NERVOUS SYSTEM DISORDERS
9.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment
TABLE 68 MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS
9.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers that help in timely diagnosis of such conditions
TABLE 70 MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.7 OTHER DISEASES
TABLE 72 MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
10 MULTIPLEX ASSAYS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 74 MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE ITS UPTAKE
TABLE 75 MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 HOSPITALS & RESEARCH INSTITUTES
10.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET
TABLE 77 MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR HOSPITALS & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 REFERENCE LABORATORIES
10.4.1 GROWING NUMBER OF CLINICAL TESTS PERFORMED IN REFERENCE LABORATORIES AND INCREASING NUMBER OF ACCREDITED LABORATORIES TO SUPPORT MARKET GROWTH
TABLE 79 MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.5 OTHER END USERS
TABLE 81 MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 82 NORTH AMERICA: MULTIPLEX ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
11 MULTIPLEX ASSAYS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 83 MULTIPLEX ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
TABLE 84 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 86 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
FIGURE 23 NORTH AMERICA: MULTIPLEX ASSAYS MARKET SNAPSHOT
11.2.1 RECESSION IMPACT ON NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 90 US: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 91 US: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 US: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 93 US: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 94 US: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increased funding activities by government in life sciences research & drug development to support market growth
TABLE 95 CANADA: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 96 CANADA: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 CANADA: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 98 CANADA: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 99 CANADA: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 100 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
TABLE 101 EUROPE: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 102 EUROPE: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 104 EUROPE: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 105 EUROPE: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 RECESSION IMPACT ON EUROPE
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET SNAPSHOT
TABLE 106 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 RECESSION IMPACT ON ASIA PACIFIC
11.5 REST OF THE WORLD
TABLE 111 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 112 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 114 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 115 REST OF THE WORLD: MULTIPLEX ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 RECESSION IMPACT ON REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
TABLE 116 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2017–2021)
12.4 MARKET SHARE ANALYSIS
12.4.1 MULTIPLEX ASSAYS MARKET
FIGURE 26 MULTIPLEX ASSAYS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 117 MULTIPLEX ASSAYS MARKET: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 27 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 28 MULTIPLEX ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE SCENARIO
12.7.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 118 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020- 2023)
12.7.2 DEALS
TABLE 119 KEY DEALS (2020-2023)
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ILLUMINA, INC.
TABLE 120 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 29 COMPANY SNAPSHOT: ILLUMINA, INC. (2022)
13.1.2 BIO-RAD LABORATORIES, INC.
TABLE 121 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2022)
13.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 122 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC. (2021)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 123 BECTON, DICKINSON AND COMPANY.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY (2022)
13.1.5 DIASORIN S.P.A.
TABLE 124 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: DIASORIN S.P.A. (2021)
13.1.6 QIAGEN N.V.
TABLE 125 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2021)
13.1.7 ABCAM PLC
TABLE 126 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: ABCAM PLC (2021)
13.1.8 MERCK KGAA
TABLE 127 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2022)
13.1.9 AGILENT TECHNOLOGIES, INC.
TABLE 128 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: AGILENT TECHNOLOGIES, INC. (2022)
13.1.10 QUANTERIX
TABLE 129 QUANTERIX: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: QUANTERIX (2022)
13.1.11 BIO-TECHNE
TABLE 130 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: BIO-TECHNE (2021)
13.1.12 MESO SCALE DIAGNOSTICS, LLC
TABLE 131 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
13.1.13 RANDOX LABORATORIES LTD.
TABLE 132 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 OLINK
TABLE 133 OLINK: COMPANY OVERVIEW
13.2.2 SEEGENE INC.
TABLE 134 SEEGENE INC.: COMPANY OVERVIEW
13.2.3 SIEMENS HEALTHINEERS AG
TABLE 135 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
13.2.4 PERKINELMER INC.
TABLE 136 PERKINELMER INC.: COMPANY OVERVIEW
13.2.5 SHIMADZU CORPORATION
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
13.2.6 PROMEGA CORPORATION
TABLE 138 PROMEGA CORPORATION: COMPANY OVERVIEW
13.2.7 ENZO BIOCHEM INC.
TABLE 139 ENZO BIOCHEM INC.: COMPANY OVERVIEW
13.2.8 CAYMAN CHEMICAL
TABLE 140 CAYMAN CHEMICAL: COMPANY OVERVIEW
13.2.9 BOSTER BIOLOGICAL TECHNOLOGY
TABLE 141 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
13.2.10 ANTIGENIX AMERICA, INC.
TABLE 142 ANTIGENIX AMERICA, INC.: COMPANY OVERVIEW
13.2.11 QUANSYS BIOSCIENCES INC.
TABLE 143 QUANSYS BIOSCIENCES INC.: COMPANY OVERVIEW
13.2.12 RAYBIOTECH LIFE, INC.
TABLE 144 RAYBIOTECH LIFE, INC.: COMPANY OVERVIEW
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
